Navigation Links
UF scientists to work with German firm in prostate cancer treatment research
Date:6/18/2008

GAINESVILLE, Fla. University of Florida department of urology officials signed an agreement Tuesday to collaborate with the German biopharmaceutical company CureVac to test an experimental therapy for advanced prostate cancer patients who no longer respond to traditional treatment.

CureVac which specializes in the therapeutic application of messenger RNA, a biomolecule that transfers genetic information from nuclear DNA to cellular protein production machinery is developing a stabilized mRNA-derived vaccine for treatment of prostate cancer.

UF researchers will conduct a phase 1/2 clinical trial of the therapy in patients from the United States with metastatic prostate cancer who no longer respond to hormone therapy. Both institutions hope the initial collaboration will result in a better biologic product to work with in the second phase of the clinical trial.

"The agreement with the University of Florida represents our first step to the U.S. as the world's leading pharmaceutical marketplace with world-class academic institutions for research and development," said Thomas Lander, M.D., managing director and chief medical officer of CureVac.

In what will be the first direct-application trial of its kind in the United States, researchers plan to test molecules that have shown the potential to stimulate an immune response against tumors when injected into the skin, potentially providing an alternative therapy for this form of cancer.

"Several studies support the therapeutic potential of mRNA for the treatment of cancer," said Johannes Vieweg, M.D., a professor and chairman of UF's department of urology who is a member of CureVac's scientific advisory board. "This, however, will be the first clinical trial in the U.S. to use the direct application route by injecting modified mRNA into the skin."

UF urology researchers have treated more than 500 patients using RNA-based dendritic cells, which have been used in vaccines to treat the cancer, but these cells are difficult to manufacture and are often limited in quantity. Researchers hope to discover whether CureVac's technology may be an equivalent or more effective therapy to stimulate tumor response, Vieweg said.

"Our extensive experience and expertise in immunological monitoring and vaccine development are of value to companies such as CureVac, I believe, making us an attractive partner to work with," Vieweg said.

The Prostate Cancer Foundation estimates nearly 200,000 men will be diagnosed with prostate cancer in the United States in 2008. Treatment options generally include surgery or radiation if patients are diagnosed at an early stage. Hormone therapy is often used when cancer has spread beyond the prostate gland.

The proposed clinical trial is expected to begin in 2009. In the first phase of the trial, researchers will seek to define the optimal dose level of the therapy, as well as establish safety and evaluate improvements needed for the regimen. A European clinical trial is also planned.


'/>"/>

Contact: Melissa M. Thompson
thompsmelissa@gmail.com
352-273-5810
University of Florida
Source:Eurekalert

Related medicine news :

1. Scientists from Granada drastically reduce the wait time for new teeth implant
2. Possible link between different forms of epilepsy found by Carnegie Mellon scientists
3. Scientists Discover Protein Involved in Fat Production
4. Twenty of Americas Most Promising Scientists Selected as 2008 Pew Scholars in the Biomedical Sciences
5. QBI neuroscientists make Alzheimers disease advance
6. EPA scientists recognized with prestigious honor
7. 2collab Survey Reveals That Scientists and Researchers are "All Business" With Social Applications
8. Scientists ID Brain Pathway That Stops Seizures
9. Scientists ID Gene Regulating Blood Glucose Levels
10. South African scientists access European research via EMBC agreement
11. Zebrafish enable scientists to study the migration of neurons that enable sexual maturity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... , ... The American public tends to feel uncomfortable about drinking recycled waste ... or well water. The recent experience with lead contaminated water in Flint, Michigan, according ... toward increasing public acceptance of recycled waste water as drinking water. , The ...
(Date:2/5/2016)... ... ... Boar’s Head Brand®, one of the nation’s leading providers of premium delicatessen ... stress out of your party preparation – follow these easy, yet delicious recipes with ... game. , “The key to hosting a successful game-day party is creating a flavorful ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Justin Scott and ... 2nd Annual No Cost Dental Day to individuals in need. The event is scheduled ... this No Cost Dental Day is to provide dental care to community members in ...
(Date:2/5/2016)... ... 05, 2016 , ... Colorize is a web theme package created ... next using Colorize's dynamic moving camera. Colorize is perfect for personal and web related ... environment with 1 to 5 focus points per scene, stage floor scene presets that ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... kitchens, recently announced the debut of their latest mobile kitchen model, featuring customizable ... organizations with modern, high-volume commercial kitchens for use anywhere in the U.S. Many ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... Calif. , Feb. 4, 2016  Edwards Lifesciences ... patient-focused innovations for structural heart disease and critical care ... accelerated share repurchase (ASR) agreement with Morgan Stanley & ... stock.  This repurchase is part of the Company,s previously ... the Company,s common stock.  --> ...
(Date:2/4/2016)... Feb. 4, 2016 Worldwide Radiology Oncology ... growth as next generation systems provide a way ... for cancer surgery. New systems pinpoint the delivery ... has been such a problem previously, limiting the ... robots take cancer surgery far beyond what has ...
(Date:2/4/2016)... Calif. , Feb. 4, 2016  SciClone ... today announced it has entered into a settlement ... Commission (SEC) fully resolving the SEC,s investigation into ... (FCPA).  Under the terms of the settlement agreement, ... $12.8 million, including disgorgement, pre-judgment interest and a ...
Breaking Medicine Technology: